Chronic lymphocytic leukaemia: open trials in Belgium

19 open trials have a site in Belgium. Registry data; only the trial team decides who can take part.

2026-525234-39-00
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Trial Treatment · Phase 1 · Janssen Cilag International
Universitair Ziekenhuis Antwerpen, Edegem · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven
Registry updated 2026-11-06
NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
ZAS Cadix (Site 1203), Antwerp · UZ Leuven-Hematology (Site 1200), Leuven
Registry updated 2026-11-06
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 2 · Loxo Oncology, Inc.
Institut Jules Bordet, Anderlecht · AZ Sint-Jan Brugge-Oostende AV, Bruges · UZ Gent, Ghent · Groupe Jolimont, La Louvière · UZ Leuven, Leuven · Clinique Saint Pierre, Ottignies · AZ Delta vzw, Roeselare · AZ Nikolaas, Sint-Niklaas · CHR Verviers - La Tourelle, Verviers
Registry updated 2026-11-04
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Universitair Ziekenhuis Gent, Gent
Registry updated 2026-11-04
NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
AZ Delta, Roeselare
Registry updated 2026-11-04
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
Universitair Ziekenhuis Antwerpen, Edegem · UZ Leuven, Leuven · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-10-23
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Universitair Ziekenhuis Antwerpen (Uza), Edegem · UZ Gent, Ghent · CHU de Liège, Liège · AZ Delta, Roeselare
Registry updated 2026-10-14
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
UZ Leuven, Leuven · A.Z. Sint-Maarten, Mechelen
Registry updated 2026-10-13
NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Trial Treatment · Phase 1/2 · Incyte Biosciences International Sàrl
Ghent university hospital, Ghent
Registry updated 2026-10-09
NCT05791409
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Trial Treatment · Phase 1/2 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Ziekenhuis Aan De Stroom, Antwerp · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-10-05
2023-510294-34-00
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Trial Treatment · Phase 3 · University Of Cologne
Ziekenhuis Aan De Stroom, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-10-01
NCT06973187
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Treatment · Phase 3 · BeOne Medicines
Institut Jules Bordet, Anderlecht · UZ Gent, Gent · AZ Groeninge, Kortrijk · CHC MontLégia, Liège · Centre Hospitalier Universitaire de Liège, Liège · Emmaues, Mechelen · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-09-28
NCT04523428
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Trial Treatment · Phase 2 · Stichting Hemato-Oncologie voor Volwassenen Nederland
UZ Leuven, Leuven · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-09-21
2023-510173-34-00
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Trial Treatment · Phase 3 · Lakefront Biotherapeutics
Antwerp University Hospital, Edegem · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-09-11
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
UZ Leuven, Leuven · Vitaz, Sint-Niklaas
Registry updated 2026-08-17
NCT07738887
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
Trial Treatment · Phase 2 · The Lymphoma Academic Research Organisation
Institut Jules Bordet, Anderlecht · Universitair Ziekenhuis Gent, Gent · Chu Helora, La Louvière · UZ Leuven, Leuven · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-07-31
NCT06104566
Global Trial in APG2575 for Patients With CLL/SLL
Trial Treatment · Phase 3 · Ascentage Pharma Group Inc.
Antwerp University Hospital, Edegem · Universitair Ziekenhuis Gent, Gent · Chu Helora, La Louvière · UZ Leuven, Leuven · Clinique Saint Pierre, Ottignies-Louvain-la-Neuve · Algemeen Ziekenhuis Delta, Roeselare · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-06-18
NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Trial Treatment · Phase 2 · University of Liege
Institut Jules Bordet, Anderlecht · Ziekenhuis Aan De Stroom, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge · Universiteit Gent, Gent · Vrije Universiteit Brussel, Jette · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2022-10-12
NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Trial Treatment · Phase 1/2 · Kartos Therapeutics, Inc.
Antwerp University Hospital (UZA), Edegem · JESSA Ziekenhuis, Hasselt · University Hospital (UZ) Leuven, Leuven
Registry updated 2022-08-04

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error